Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model.

作者: Ken Matsumoto , Naoshi Obara , Masatsugu Ema , Masaki Horie , Ayano Naka

DOI: 10.1111/J.1349-7006.2009.01249.X

关键词:

摘要: Hypoxia-inducible factor 1 (HIF-1) plays essential roles in tumor angiogenesis and growth by regulating the transcription of several key genes response to hypoxic stress factors. HIF-1 is a heterodimeric transcriptional activator consisting inducible alpha constitutive beta subunits. In oxygenated cells, proteins containing prolyl hydroxylase domain (PHD) directly sense intracellular oxygen concentrations. PHDs tag HIF-1alpha subunits for polyubiquitination proteasomal degradation hydroxylation using 2-oxoglutarate (2-OX) dioxygen. Our recent studies showed that 2-OX reduces HIF-1alpha, erythropoietin, vascular endothelial (VEGF) expression hepatoma cell line Hep3B when under conditions vitro. Here, we report similar results were obtained Lewis lung cancer (LLC) cells vitro studies. Furthermore, potent antitumor effects mouse dorsal air sac assay murine xenograft model. assay, reduced numbers newly formed vessels induced LLC cells. model, intraperitoneal injection significantly inhibited tissues. Moreover, 5-fluorouracil combined with this which was accompanied reduction Vegf gene These suggest promising anti-angiogenic therapeutic agent.

参考文章(38)
I.J. Rondon, L.A. MacMillan, B.S. Beckman, M.A. Goldberg, T. Schneider, H.F. Bunn, J.S. Malter, Hypoxia up-regulates the activity of a novel erythropoietin mRNA binding protein. Journal of Biological Chemistry. ,vol. 266, pp. 16594- 16598 ,(1991) , 10.1016/S0021-9258(18)55342-4
G.L. Wang, G.L. Semenza, Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. Journal of Biological Chemistry. ,vol. 268, pp. 21513- 21518 ,(1993) , 10.1016/S0021-9258(20)80571-7
Patrick H. Maxwell, Michael S. Wiesener, Gin-Wen Chang, Steven C. Clifford, Emma C. Vaux, Matthew E. Cockman, Charles C. Wykoff, Christopher W. Pugh, Eamonn R. Maher, Peter J. Ratcliffe, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature. ,vol. 399, pp. 271- 275 ,(1999) , 10.1038/20459
Louis M. Sherwood, Edith E. Parris, Judah Folkman, Tumor Angiogenesis: Therapeutic Implications New England Journal of Medicine. ,vol. 285, pp. 1182- 1186 ,(1971) , 10.1056/NEJM197111182852108
Giampietro Gasparini, Raffaele Longo, Masakazu Toi, Napoleone Ferrara, None, Angiogenic inhibitors: a new therapeutic strategy in oncology Nature Clinical Practice Oncology. ,vol. 2, pp. 562- 577 ,(2005) , 10.1038/NCPONC0342
Donald R. Senger, Livingston Van De Water, Lawrence F. Brown, Janice A. Nagy, Kiang-Teck Yeo, Tet-Kin Yeo, Brygida Berse, Robert W. Jackman, Ann M. Dvorak, Harold F. Dvorak, Vascular permeability factor (VPF, VEGF) in tumor biology Cancer and Metastasis Reviews. ,vol. 12, pp. 303- 324 ,(1993) , 10.1007/BF00665960
David W Leung, George Cachianes, Wun-Jing Kuang, David V Goeddel, Napoleone Ferrara, None, Vascular endothelial growth factor is a secreted angiogenic mitogen Science. ,vol. 246, pp. 1306- 1309 ,(1989) , 10.1126/SCIENCE.2479986
Hari S. Sharma, Martin Wünsch, Thomas Brand, Pieter D. Verdouw, Wolfgang Schaper, Molecular biology of the coronary vascular and myocardial responses to ischemia. Journal of Cardiovascular Pharmacology. ,vol. 20, ,(1992) , 10.1097/00005344-199206201-00006
Olli Arjamaa, Mikko Nikinmaa, Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Experimental Eye Research. ,vol. 83, pp. 473- 483 ,(2006) , 10.1016/J.EXER.2006.01.016